Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab therapy for idiopathic macular telangiectasia

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the efficacy of intravitreal bevacizumab for the treatment of idiopathic macular telangiectasia (IMT).

Methods

Ten eyes of eight consecutive patients with IMT were studied. Four eyes had type 1, and six had type 2 IMT according to Yannuzzi’s classification. All patients were treated with intravitreal bevacizumab (1.25 mg) injections at baseline. Monthly fundus and optical coherence tomography (OCT) examinations were performed. Changes in visual acuity, macular edema on OCT, and leakage on fluorescein angiography were analyzed during 6 months of follow-up. Retreatment was considered when increased macular edema and either fluorescein leakage or visual loss were identified.

Results

There were no changes in the mean visual acuity in either eye in any of the patients. In one of the four eyes with type 1 IMT, the microaneurysms disappeared after bevacizumab treatment. However, there were no changes in the other three eyes. Fluorescein leakage disappeared in four, decreased in one, and was unchanged in one of the eyes with type 2 IMT. An inner lamellar cyst in each eye was unchanged in two, newly formed in one, and expanded in one eye with type 2 IMT.

Conclusion

Type 2 IMT improved anatomically with bevacizumab treatment despite a lack of improvement in vision. Bevacizumab effectively decreases vascular permeability and retinal edema in the short term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769–780.

    CAS  PubMed  Google Scholar 

  2. Gass JDM, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis: update of classification and follow-up study. Ophthalmology 1993;100:1536–1546.

    CAS  PubMed  Google Scholar 

  3. Yannuzzi LA, Bardal AMC, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthamol 2006;124:450–460.

    Article  Google Scholar 

  4. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.

    CAS  PubMed  Google Scholar 

  5. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11–16.

    Article  CAS  PubMed  Google Scholar 

  6. Kovach JL, Rosenfeld PJ. Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27–32.

    Article  PubMed  Google Scholar 

  7. Charbel Issa P, Finger RP, Holtz FG, Scholl HP. Eighteen-months follow up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2007;92:941–945.

    Article  Google Scholar 

  8. Moon SJ, Berger AS, Misch DM. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmol Surg Lasers Imaging 2007;38:164–166.

    Google Scholar 

  9. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Ophthalmol 2008;246:1189–1193.

    Article  CAS  Google Scholar 

  10. Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838–1846.

    CAS  PubMed  Google Scholar 

  11. Cakir M, Kapran Z, Basar D, Utine CA, Eroglu F, Perente I. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Euro J Ophthalmol 2006;16:711–717.

    CAS  Google Scholar 

  12. Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006;26:780–785.

    Article  PubMed  Google Scholar 

  13. Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Ophthalmol 2007;245:1045–1048.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Nihon University Hospital, Tokyo, Japan

    Yoko Matsumoto & Mitsuko Yuzawa

  2. Department of Ophthalmology, Nihon University Hospital, 1-8-13 Surugadai Kanda, Chiyoda-ku, Tokyo, 101-8309, Japan

    Yoko Matsumoto

Authors
  1. Yoko Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuko Yuzawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoko Matsumoto.

About this article

Cite this article

Matsumoto, Y., Yuzawa, M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 54, 320–324 (2010). https://doi.org/10.1007/s10384-010-0810-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-010-0810-4

Keywords

Search

Navigation